BLACK DIAMOND THERAPEUTICS, INC. Income (Loss) Attributable to Parent, before Tax
BLACK DIAMOND THERAPEUTICS, INC. (BDTX) reported Income (Loss) Attributable to Parent, before Tax of $22.36 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-16.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossAttributableToParent · last filed 2026-03-16
- BLACK DIAMOND THERAPEUTICS, INC. income (loss) attributable to parent, before tax for fiscal 2025 was $22.36M.
- BLACK DIAMOND THERAPEUTICS, INC. income (loss) attributable to parent, before tax for fiscal 2024 was -$69.68M.
- BLACK DIAMOND THERAPEUTICS, INC. income (loss) attributable to parent, before tax for fiscal 2023 was -$82.44M.
- BLACK DIAMOND THERAPEUTICS, INC. income (loss) attributable to parent, before tax for fiscal 2022 was -$91.17M.
| Period end | Income (Loss) Attributable to Parent, before Tax 12 month |
|---|---|
| 2025-12-31 | $22.36M 10-K · filed 2026-03-16 |
| 2024-12-31 | -$69.68M 10-K · filed 2026-03-16 |
| 2023-12-31 | -$82.44M 10-K · filed 2025-03-06 |
| 2022-12-31 | -$91.17M 10-K · filed 2024-03-12 |
| 2021-12-31 | -$125.60M 10-K · filed 2023-03-09 |
| 2020-12-31 | -$67.25M 10-K · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |